Matsuoka T, Okamoto Y, Matsuzaki Z, Endo S, Ito E, Tsutsumi H, Williamson R A, Sakurai H, Burton D R, Saito I
Department of Otolaryngology, Yamanashi Medical University, Japan.
Clin Exp Immunol. 2002 Dec;130(3):386-92. doi: 10.1046/j.1365-2249.2002.02003.x.
The characteristics of the immunity induced by viral antigens or conferred by antiviral antibody via different routes of administration were evaluated comparatively. C57BL/6 mice were immunized via intranasal, intradermal or enteric routes with a live recombinant vaccinia virus expressing the respiratory syncytial virus (RSV) F glycoprotein (F.rVV) or RSV, and then challenged intranasally with RSV. Inhibition of RSV replication was observed in the lungs of all the mice; however, only intranasal immunization hindered virus replication in the nose. Lung inflammation, characterized by infiltration of neutrophils and of mononuclear cells was strongest in the intradermally immunized mice, but was observed in all F.rVV immunized mice to various degrees. Intranasal administration of a potently neutralizing human anti-RSV antibody Fab fragment to infected mice inhibited RSV replication in the nose and, when combined with intraperitoneal administration, protected both the lung and the nose in the absence of deleterious lung pathology. These data suggest that intranasal immunization with F.rVV reduces RSV replication in the respiratory tract, but still induces pathological lung inflammation, even though this is milder than that observed following intradermal immunization. Local neutralizing antibody is indispensable for protection in the nose.
比较评估了通过不同给药途径由病毒抗原诱导或由抗病毒抗体赋予的免疫特性。用表达呼吸道合胞病毒(RSV)F糖蛋白的重组活痘苗病毒(F.rVV)或RSV经鼻内、皮内或肠道途径免疫C57BL/6小鼠,然后经鼻内用RSV攻击。在所有小鼠的肺中均观察到RSV复制受到抑制;然而,只有鼻内免疫能阻碍病毒在鼻内的复制。以中性粒细胞和单核细胞浸润为特征的肺部炎症在皮内免疫的小鼠中最为强烈,但在所有F.rVV免疫的小鼠中均有不同程度的观察到。向感染小鼠鼻内给予强效中和性人抗RSV抗体Fab片段可抑制RSV在鼻内的复制,并且当与腹腔内给药联合使用时,在没有有害肺部病理变化的情况下可保护肺和鼻。这些数据表明,用F.rVV进行鼻内免疫可减少呼吸道中RSV的复制,但仍会诱导肺部病理性炎症,尽管其程度比皮内免疫后观察到的要轻。局部中和抗体对于鼻内的保护是必不可少的。